NEW YORK (GenomeWeb News) — MedImmune yesterday said it has licensed its reverse genetics intellectual property to Novartis to help the drug maker develop new influenza vaccine strains.

 

Terms of the deal call for MedImmune to receive an upfront payment from Novartis, as well as the potential to receive royalties on certain vaccine stockpiles or sales of other influenza products developed using the reverse genetics technology.